1 sified within the spectrum of neuroendocrine lung neoplasms.

2  23 cases after thoracoscopic procedures for lung neoplasms.

3 f patients after percutaneous RFA and MWA of lung neoplasms.

4 ays in the diagnosis of cytologically occult lung neoplasms.

5  a frequent mutational target in RNR-induced lung neoplasms.

6 tochemically examined in archival samples of lung neoplasms (adenomas, adenocarcinomas, and adenosqua

7  represent new and effective therapy against lung neoplasms and potentially tumors of other origin.

8 y on breast neoplasms, colorectal neoplasms, lung neoplasms, and 32 other diseases demonstrated the a

9 ow easier comparison between human and mouse lung neoplasms, (b) accommodate newly emerging mouse neo

10 patients treated with MWA and/or RFA for 195 lung neoplasms between February 2004 and April 2010.

11                                              Lung neoplasms commonly develop in patients previously t

12 d tissue samples of 41 AAHs and their paired lung neoplasms from 28 patients for codon 12 point mutat

13                     Importantly, RNR-induced lung neoplasms histopathologically resemble human papill

14 ropulmonary blastoma (PPB) is a rare, cystic lung neoplasm in infants characterized by subtle maligna

15 ntervertebral disc protrusion, and malignant lung neoplasm in the acetylcysteine group, and aortic an

16 RNR subunit potently and selectively induces lung neoplasms in transgenic mice and is mutagenic in cu

17 e 18 adenocarcinomas, and none (0%) of the 5 lung neoplasms that were not adenocarcinomas.